

# Development and evaluation of i-Tracker Golimumab and i-Tracker Anti-Golimumab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with Golimumab

Theradias
INNOVATION FOR BIOTHERAPIES

I—Trackie

I—Trackie

Total Mean (μg/ml)

0.5

1.0

3.2%

0.0%

6

0.5

5

0.5

4

0.5

1.0

<u>C. Montaillier<sup>1</sup></u>, V. Guilbert<sup>1</sup>, <u>G. Khater<sup>2</sup></u>, S. Daviere<sup>2</sup>, G. Noguier<sup>1</sup>. <sup>1</sup>Theradiag, Research and Development, Croissy-Beaubourg, France. <sup>2</sup>Theradiag, Theranostics, Croissy-Beaubourg, France.

### **INTRODUCTION**

Golimumab, a monoclonal antibody directed against TNFα, is a drug widely used for the treatment of inflammatory diseases (ulcerative colitis, Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, ...). Therapeutic Drug Monitoring is currently proposed to provide useful information to clinicians to improve the efficacy of the treatment. Theradiag has just developed the innovative **i-Tracker** kits: fast quantification of Golimumab and Anti-Golimumab antibodies fully automated on the random access **i-Track**<sup>10</sup> chemiluminescent analyzer.

#### **MATERIALS & METHODS**

#### **MATERIALS:**


Golimumab SPIKED SAMPLES: 3 human serum matrices (from healthy donors) were used. The drug, Golimumab pharmaceutical solution (100 mg/mL), was spiked into these 3 matrices to reach 5 concentration levels spanning the dynamic range of the assay (0.5, 1, 3, 4.5 and 6  $\mu$ g/mL). A total of 15 spiked samples were produced. % of recovery was calculated according to the following formula : (quantified concentration/spiked concentration) x 100.

CLINICAL SAMPLES: 60 serum samples from Crohn's disease patients treated with Golimumab were collected. They arrived frozen and kept frozen until quantification at Theradiag. Additionally, 24 serum samples, previously quantified for Anti-Golimumab antibodies with LISA TRACKER Anti-Golimumab assay (#LTG 005, Theradiag) were used for correlation assessment.

**i-Tracker** Golimumab kit: composed of monoclonal anti-Golimumab antibody (anti-idiotype) coated magnetic beads, polyclonal anti-Golimumab antibodies conjugated to acridinium ester, and sample dilution buffers. **i-Tracker** Anti-Golimumab kit: composed of Golimumab coated magnetic beads, Golimumab conjugated to acridinium ester, and sample dilution buffer. Both types of kit contain 2 calibrators and 1 positive control dedicated for the calibration process (master curve) and for the validation of the run, respectively. Once performed, calibration is valid for 21 days.


## METHODS:

**i-Tracker** CHEMILUMINESCENT ASSAYS: quantification of Golimumab and Anti-Golimumab antibodies were performed with the **i-Track**<sup>10</sup> chemiluminescent analyzer according to the technical insert of **i-Tracker** kits (#CTG 002 and #CTG 003 respectively). Briefly, serum samples were diluted and added to the coated magnetic beads suspension. After incubation of 15 minutes at +37°C, beads were washed and acridinium ester (AE) conjugate was added. After 15 minutes of incubation at +37°C, beads were washed, and triggers were added. Instantly, relative light emissions (RLU) were detected and quantified by **i-Track**<sup>10</sup> chemiluminescent analyzer. Concentrations of Golimumab and Anti-Golimumab antibodies were calculated according to the calibration curve provided with the kit (master curve). The lower and the upper limits of quantification are 0.3  $\mu$ g/mL and 8  $\mu$ g/mL for **i-Tracker** Golimumab assay, 10 ng/mL and 2000 ng/mL for **i-Tracker** Anti-Golimumab assay.



# RESULTS 1/2

**ACCURACY** (see figure below): 15 Golimumab spiked samples were quantified with **i-Tracker** Golimumab. The % of recovery were comprised between 87% and 105% (mean % of recovery was 95%).



# Conclusion:

The acceptance criteria were met (% recovery comprised +/- 20% of spiked concentrations for > 80% samples). Quantification of Golimumab with **i-Tracker** Golimumab is not affected by serum matrix.

## RESULTS 2/2

LLOQ (Lower Limit Of Quantification): on one hand, 115 serum samples from untreated patients were quantified with i-Tracker Golimumab: all samples were found below the selected LLOQ of 0.3 µg/mL. On the other hand, 108 samples from untreated patients were quantified with i-Tracker Anti-Golimumab: all samples were found below the selected LLOQ of 10 ng/mL.

INTRA-RUN PRECISION (see figures on the right): for both assays, 5 clinical samples spanning the dynamic range of the respective assays were quantified 10 times within a run. The coefficients of variation (CV) were calculated for each sample: the CV ranged from 0% to 11.5% for Golimumab assay and between 1.3% and 11.9% for Anti-Golimumab assay.

INTER-RUN PRECISION (see figures on the right): for both assays 5 clinical samples spanning the dynamic range of the respective assays were quantified on 6 independent runs. The coefficients of variation (CV) were calculated for each sample: the CV ranged from 1.6% to 2.3% for Golimumab assay, and CV ranged from 0% to 4.4% for Anti-Golimumab assay. The acceptance criteria (CV<20%) was met. High precision is reached with i-Tracker Golimumab assay and i-Tracker Anti-Golimumab assay.

D		Golimuma	nb			Anti-Golimum	nab	
Sample 1	ID			CV	ID	results (ng/ml)	mean (ng/mL)	I
Sample 1  0.3			μεσιι (μες/ ιτι.)					ſ
Sample 1  0.4  0.4  0.4  0.4  0.4  0.4  0.4  0.						40		۱
Sample 1				8.1%		42		
Sample 1  0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.						41		
Sample 1  0.4  0.4  0.4  0.4  0.4  0.4  0.4  0.					Complete 1			
Sample 2  0.4  0.4  0.4  0.4  0.4  0.4  0.4  0.	Sample 1		0.4		Sample 1			1.39
Sample 2  0.4  0.4  0.4  0.4  0.4  0.4  0.4  40  40								
Sample 2								
Sample 2  1.0  1.0  1.0  1.0  1.0  1.0  1.0  1.								
Sample 2  1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.								l
Sample 2  1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.								t
Sample 2  1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.								I
Sample 2    1.0								1.4
Sample 2  1.0  1.0  1.0  1.0  1.0  1.0  1.0  1.								
Sample 2  1.0  1.0  1.0  1.0  1.0  1.0  1.0  1.								
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	Sample 2		1.0		Sample 2		77	
Sample 3  Sample 3  Sample 4	•							
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0								
Sample 3  Sample 3  Sample 3  Sample 4  Sample 4  Sample 4  Sample 4  Sample 5  Sample 5  Sample 5  Sample 6.2  Sample 6.2  Sample 6.2  Sample 7  77  202  1127  167  183  190  178  194  166  185  185  185  185  760  763  757  780  763  757  780  751  769  777  766  777  766  1319  1319  1319  1319  1319  13144  1344  1344  1344  1344  1344  1344  1344  1344  1344								
Sample 3  2.7  2.5  2.8  2.6  2.6  2.6  2.6  2.6  2.6  2.6								
Sample 3  2.5 2.8 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.4  4.3 3.5 3.5 3.5 4.5 3.7 780 780 751 780 777 4.2 4.7 3.5 4.2 4.7 3.5 6.2 6.1 6.5 6.2 6.2 6.2 6.3 6.2 6.3 6.2 6.4 6.4 6.2  8 Sample 5  127 167 183 190 178 194 166 185 185 760 763 757 780 753 751 765 777 766 777 777 766 777 1 3.5  Sample 5  Sample 6  Sample 5  Sample 7  Sample 7  Sample 8  Sample 8  Sample 8  Sample 9  Sample								ł
Sample 3  2.8 2.6 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.4  4.3 3.5 3.5 4.5 3.7 4.2 4.5 4.2 4.7 3.5 4.2 4.7 3.5 6.2 6.1 6.5 6.2 6.2 6.2 6.3 6.2 6.3 6.2 6.4 6.2 6.4 6.2  4.2%  Sample 3  Sample 3  167 183 190 178 1183 190 178 1183 190 178 178 194 166 185 185 760 763 757 780 757 780 751 765 777 766 771 776 766 771 1319 1319 1319 1319 1319 1319 1319	Sample 2	2.7					178	
Sample 3  2.6 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.4 4.3 3.5 3.5 4.5 3.5 4.5 4.2 4.1 11.5%  Sample 4  Sample 4  Sample 4  Sample 5  Sample 5  Sample 5  Sample 5  Sample 5  Sample 5  Sample 6  Sample 6  Sample 7  Sample 8  Sample 8  Sample 9  S		2.5						l
Sample 3  2.7  2.6  2.6  2.6  2.6  2.6  2.6  2.6		2.8	4.1					l
Sample 3  2.6  2.6  2.6  2.6  2.6  2.6  2.4  4.3  3.5  3.5  3.5  4.5  4.2  4.1  11.5%  Sample 4  Sample 5  Sample 5  Sample 5  Sample 5  Sample 5  Sample 6  178  194  166  185  185  760  763  763  757  780  765  780  771  766  777  766  777  766  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 314  1 317  1 318  1 319  1 319  1 319  1 319  1 314  1 317  1 318  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 319  1 314  1 317  1 314  1 317  1 314  1 317  1 314		2.6			-			
Sample 4  2.6 2.6 2.6 2.6 2.6 2.4  4.3 3.5 3.5 3.5 4.5 3.7 757 780 753 751 769 771 766 4.2 4.7 3.5  6.2 6.1 6.5 6.2 6.2 6.3 6.2 6.4 6.4 6.2  5ample 5  194 166 185 185 760 776 780 771 780 765 771 780 771 766 777 766 1319 1319 1319 1344 1344 1347 1363		2.7			Sample 3			I
Sample 4  2.6 2.6 2.6 2.4  4.3 3.5 3.5 3.5 4.5 3.7 760 763 757 780 753 780 753 757 780 769 777 766 777 766 771 3.5  6.2 6.1 6.5 6.2 6.2 6.3 6.2 6.3 6.2 6.4 6.4 6.2  1352 1352 1352 1352	Sample S	2.6						
Sample 4  2.6  2.4  4.3  3.5  3.5  4.5  3.7  4.2  4.5  4.1  11.5%  Sample 4  Sample 4  Sample 5  Sample 5  185  760  763  757  780  753  755  777  766  777  766  777  766  771  3.5  1319  1319  1319  1319  1344  1378  1344  1378  1344  1378  1344  1352  1344  1357  1344  1357  1344  1357  1344  1357		2.6						
Sample 4  2.4  4.3  3.5  3.5  4.5  3.7  4.2  4.7  3.5  4.2  4.7  3.5  6.2  6.1  6.5  6.2  6.3  6.2  6.3  6.2  6.4  6.5  6.2  6.4  6.5  6.2  6.3  6.2  6.3  6.2  6.4  6.5  6.2  6.3  6.2  6.3  6.2  6.3  6.2  6.3  6.3		2.6		11.5%				
Sample 4  4.3  3.5  3.5  4.5  4.1  11.5%  Sample 4  Sample 4  Sample 4  For a series of the series o		2.6						
Sample 4  4.3  3.5  3.5  4.5  4.1  11.5%  Sample 4  Sample 4  Sample 4  For including the problem of the proble								ļ
Sample 4  3.5 3.5 4.5 4.1  11.5%  Sample 4  5ample 4  5ample 4  5ample 4  5ample 4  757 780 753 765 769 777 766 777 766 771  3.5  6.2 6.1 6.5 6.2 6.2 6.3 6.2 6.3 6.2 6.4 6.4 6.2  1352  1352  1352							765	
Sample 4  3.5 4.5 3.7 4.2 4.5 4.2 4.7 3.5 4.2 4.7 3.5 6.2 6.1 6.2 6.2 6.3 6.2 6.2 6.4 6.2 6.4 6.2 6.4 6.2 6.4 6.5 6.2 751 769 777 766 771  3.55  Sample 5  Sample 5  Sample 5  Sample 5  Sample 5  Sample 5  1319 1344 1344 1347 1352								١
Sample 4  4.5  3.7  4.2  4.5  4.5  4.2  4.7  3.5  6.2  6.1  6.5  6.2  6.2  6.3  6.2  6.3  6.2  6.4  6.5  6.2  1344  1357  1344  1347  1363								
Sample 4  3.7  4.2  4.5  4.7  3.5  6.2  6.1  6.5  6.2  6.2  6.3  6.2  6.3  6.2  6.4  6.2  6.4  6.5  6.2  1357  1363  765  765  765  765  765  765  765								1.3
Sample 4  4.2  4.5  4.7  4.7  3.5  6.2  6.1  6.5  6.2  6.2  6.3  6.2  6.3  6.2  6.4  6.4  6.5  6.2  1357  1352  Sample 5  Sample 5  Sample 5					Sample 4			
4.5 4.2 4.7 766 771 3.5 6.2 6.1 6.5 6.2 6.2 6.3 6.2 6.3 6.2 6.4 6.4 6.5 1357 1344 1347 1363	Sample 4				'			
4.2 4.7 3.5  6.2 6.1 6.5 6.2 6.2 6.3 6.2 6.3 6.2 6.4 6.4 6.5 6.2 771  319 1319 1344 1344 1352 1352								
A.7  3.5  6.2  6.1  6.5  6.2  6.3  6.2  6.3  6.2  6.4  6.4  6.4  6.5  1344  1352  1352  1352								
3.5 6.2 6.1 6.5 6.2 6.2 6.3 6.2 6.3 6.2 6.4 6.4 6.4 6.5 1344 1352 1352 1344 1347 1363								
Sample 5  6.2 6.1 6.5 6.2 6.2 6.3 6.2 6.3 6.2 6.4 6.4 6.4 6.5 1344 1352 1357 1344 1347 1363								ļ
Sample 5  6.1  6.5  6.2  6.3  6.2  6.3  6.2  6.4  6.4  6.5  1 344  1 347  1 347  1 363								ĺ
Sample 5  6.5 6.2 6.2 6.3 6.2 6.3 6.2 6.4 6.4 6.2 6.4 1344 1347 1363								١
Sample 5  6.2 6.2 6.3 6.2 6.2 6.4 6.4 6.2 6.4 6.2 6.5 1344 1357 1344 1347 1363								
Sample 5  6.2 6.3 6.2 6.4 6.4 6.2 6.2 1352  Sample 5  1405 1357 1344 1347 1363				2.0%			1352	١
Sample 5  6.3  6.2  6.4  6.2  1347  1363					Sample 5			1.99
6.3 6.2 6.4 6.4 6.2 1 347 1 363	Sample 5				Janipie 3			
6.4 6.2 1 347 1 363								
6.2						1 344		١
						1 347		١
		6.2				1 363		

(low)	1.0	1.0	1 2.0	1.0	1.0	1.0	1.0	
Sample3 (mid)	2.6	2.6	2.6	2.6	2.6	2.7	2.6	1.9%
Sample4 (high)	4.5	4.2	4.0	4.3	4.5	4.4	4.3	4.4%
Sample5 (high)	6.2	6.4	6.1	6.3	6.3	6.3	6.3	1.6%
Sample6 (high)	7.9	7.9	8.0	8.1	8.1	8.1	8.0	1.2%
		ANTI-GO	LIMUMAE	<b>B ASSAY</b>				
RUNS	1	2	3	4	5	6	Total Mean (ng/ml)	CV
RUNS Sample1 (low)	<b>1</b> 36	<b>2</b> 38	<b>3</b> 38	38	<b>5</b> 37	<b>6</b> 38	Total Mean (ng/ml) 37	CV 2.2%
Sample1			_					
Sample1 (low) Sample2	36	38	38	38	37	38	37	2.2%
Sample1 (low) Sample2 (mid) Sample3	36 65	38 68	38 70	38 70	37 75	38 74	37 70	2.2% 5.2%

**GOLIMUMAB ASSAY** 


0.5

**INTERFERENCES** (see figures below): spiked samples (low and high level) were made with Golimumab and Anti-Golimumab antibodies with or without the presence of potential interfering agents, as bilirubin, hemoglobin, triglycerides, rheumatoid factors (RF) and biotin. Golimumab spiked samples spiked with potential interfering agents were quantified with **i-Tracker** Golimumab kit and compared to results obtained with Golimumab spiked samples. Same method was performed with Anti-Golimumab antibodies spiked samples. The percentages of bias (% of variation between samples with/without interfering agents) were low (within +/- 20%).

**RUNS** 

Sample1


Sample2



**Conclusion: i-Tracker** assays are not disrupted by the presence of biologic agents as bilirubin (0.2 mg/mL), hemoglobin (2 mg/mL), triglycerides (33mg/ml), rheumatoid factors (1000 AU/mL) and biotin ( $2\mu g/mL$ ).

# **CORRELATIONS** (see figure below):

On one hand, 60 clinical samples (from Crohn's disease patients) were quantified for Golimumab with **i-Tracker** Golimumab and LISA TRACKER Golimumab (Theradiag). Concentrations were plotted on a "x/y" axis and a linear regression was performed. High correlation was observed:  $R^2 = 0.91$  and slope = 0.90.



On the other hand, 24 samples were quantified for Anti-Golimumab antibodies with i-Tracker Anti-Golimumab and LISA TRACKER Anti-(Theradiag). For Golimumab both assays, concentrations were ranked, and correlation observed Spearman's was coefficient was found at 0.99 (see figure below).

